Advertisement

Internal and Emergency Medicine

, Volume 3, Issue 2, pp 171–173 | Cite as

Successful outcome of DIC and life-threatening bleeding in a toddler with neuroblastoma treated with recombinant activated factor VII

  • Emmanouil S. Hatzipantelis
  • Nikolaos GombakisEmail author
  • Vasiliki Sidi
  • Evgenia Papakonstantinou
  • Dimitrios E. Koliouskas
CE - Letter to the Editor

Bleeding in disseminated intravascular coagulation (DIC) associated with advanced or metastatic tumors is often difficult to control by conventional methods [1]. The standard treatment includes red blood cells, (RBC), fresh frozen plasma (FFP), cryoprecipitate, and platelet concentrates. However, such replacement therapy is associated with increased risks of morbidity and mortality [2]. Sallah et al. [1] reported the use of rFVIIa in 18 patients with cancer and bleeding secondary to DIC; 15 of them responded to the treatment with improvement in coagulation laboratory data and arrest in bleeding. Here we report on the use of rFVIIa in a 16-month-old boy with metastatic bilateral neuroblastoma and massive bleeding secondary to DIC.

The boy presented with pallor and abdominal distension, due to a large palpable mass. Image studies revealed an unresectable extending bilaterally tumor with lymph node involvement and bone marrow infiltration. Fine-needle biopsy confirmed the diagnosis of...

Keywords

Neuroblastoma Tissue Factor Disseminate Intravascular Coagulation Fresh Freeze Plasma Fresh Freeze Plasma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Sallah S, Husain A, Nguyen-Nam P (2004) Recombinant activated factor VII in patients with cancer and hemorrhagic disseminated intravascular coagulation. Blood Coagul Fibrinolysis 15(7):577–582PubMedGoogle Scholar
  2. 2.
    Malone DL, Dune J, Tracy JK, Putnam AT, Scalea TM, Napolitano LM (2003) Blood transfusion, independent of shock severity, is associated with worse outcome in trauma. J Trauma 54:898–907PubMedCrossRefGoogle Scholar
  3. 3.
    Von Depka M. Novoseven (2002) Mode of action and use in acquired haemophilia. Intensive Care Med 28:222–227CrossRefGoogle Scholar
  4. 4.
    Kenet G, Walden R, Eldad A, Martinowitz U (1999) Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 354:1879PubMedCrossRefGoogle Scholar
  5. 5.
    Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerslev J, Lynn M (2001) Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 51:431–439PubMedGoogle Scholar
  6. 6.
    Grounds M (2003) Recombinant factor VIIa (rFVIIa) and its use in severe bleeding in surgery and trauma: a review. Blood Rev 17:11–21CrossRefGoogle Scholar
  7. 7.
    Friederich PW, Henny CP, Messelink FJ, Geerdink MG, Keller T, Kurth KH, Buller HR, Levi M (2003) Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 361:201–205PubMedCrossRefGoogle Scholar
  8. 8.
    Deveras RA, Kessler CM (2002) Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 137:884–888PubMedGoogle Scholar
  9. 9.
    Hedner U. Recombinant factor VIIa (Novoseven) as a hemostatic agent. Dis Mon 49:39–48Google Scholar
  10. 10.
    Roberts HR, Monroe DM, White GC (2004) The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 104:3858–3864PubMedCrossRefGoogle Scholar
  11. 11.
    Hoffman M (2003) A cell-based model of coagulation and the role of factor VIIa. Blood Rev 17(Suppl 1):1–5CrossRefGoogle Scholar
  12. 12.
    Roberts HR (2001) Factor VIIa and the safety of treatment. Semin Hematol 38(suppl 12):48–50PubMedCrossRefGoogle Scholar
  13. 13.
    Levi M (2003) Safety of recombinant factor VIIa. TATM 5:11–14Google Scholar
  14. 14.
    Martinowitz U, Michaelson M (2005) Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli multidisciplinary rFVIIa task force. J Thromb Haemost 3:640–648PubMedCrossRefGoogle Scholar

Copyright information

© SIMI 2008

Authors and Affiliations

  • Emmanouil S. Hatzipantelis
    • 1
  • Nikolaos Gombakis
    • 2
    Email author
  • Vasiliki Sidi
    • 1
  • Evgenia Papakonstantinou
    • 1
  • Dimitrios E. Koliouskas
    • 1
  1. 1.Paediatric Oncology Department“Hippokration” General Hospital of ThessalonikiThessalonikiGreece
  2. 2.1st Paediatric Department of Aristotle University of Thessaloniki“Hippokration” General HospitalThessalonikiGreece

Personalised recommendations